Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera Inc. stock logo
BFRIW
Biofrontera
$0.02
$0.03
$0.02
▼
$0.15
N/AN/A5,940 shs47 shs
CINGW
Cingulate
$0.01
-21.1%		$0.01
$0.00
▼
$0.12
N/AN/A32,408 shs1,869 shs
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$0.03
-1.4%		$0.03
$0.02
▼
$0.15
N/AN/A9,625 shs557 shs
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
$0.01
$0.00
▼
$0.10
$14K-16.551,322 shs103 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera Inc. stock logo
BFRIW
Biofrontera
0.00%+3.00%-29.93%-8.44%-80.69%
CINGW
Cingulate
-21.05%-13.42%-49.15%-74.90%-88.68%
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
-1.42%+0.29%-1.98%-2.53%-22.02%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00%+11,000.00%+5,450.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera Inc. stock logo
BFRIW
Biofrontera
$0.02
$0.03
$0.02
▼
$0.15
N/AN/A5,940 shs47 shs
CINGW
Cingulate
$0.01
-21.1%		$0.01
$0.00
▼
$0.12
N/AN/A32,408 shs1,869 shs
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$0.03
-1.4%		$0.03
$0.02
▼
$0.15
N/AN/A9,625 shs557 shs
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
$0.01
$0.00
▼
$0.10
$14K-16.551,322 shs103 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera Inc. stock logo
BFRIW
Biofrontera
0.00%+3.00%-29.93%-8.44%-80.69%
CINGW
Cingulate
-21.05%-13.42%-49.15%-74.90%-88.68%
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
-1.42%+0.29%-1.98%-2.53%-22.02%
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00%+11,000.00%+5,450.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biofrontera Inc. stock logo
BFRIW
Biofrontera
0.00
N/AN/AN/A
CINGW
Cingulate
0.00
N/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
0.00
N/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biofrontera Inc. stock logo
BFRIW
Biofrontera
$46.18MN/AN/AN/AN/AN/A
CINGW
Cingulate
N/AN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
$1.11MN/AN/AN/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/A$1.65 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/AN/AN/AN/AN/AN/AN/AN/A11/18/2026 (Estimated)
CINGW
Cingulate
N/AN/AN/AN/AN/AN/AN/AN/A11/18/2026 (Estimated)
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
-$15.19M-$123.25N/AN/AN/AN/A-1,554.34%-338.29%11/19/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/AN/AN/AN/AN/A
CINGW
Cingulate
N/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/AN/AN/A
CINGW
Cingulate
N/AN/AN/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
N/A
0.13
0.13

Institutional Ownership

CompanyInstitutional Ownership
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/A
CINGW
Cingulate
N/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
32.23%

Insider Ownership

CompanyInsider Ownership
Biofrontera Inc. stock logo
BFRIW
Biofrontera
N/A
CINGW
Cingulate
N/A
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
N/A
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biofrontera Inc. stock logo
BFRIW
Biofrontera
70N/AN/ANot Optionable
CINGW
Cingulate
20N/AN/ANot Optionable
60 Degrees Pharmaceuticals, Inc. stock logo
SXTPW
60 Degrees Pharmaceuticals
2N/AN/ANot Optionable
Virpax Pharmaceuticals, Inc. stock logo
VRPX
Virpax Pharmaceuticals
71.24 million4.71 millionNot Optionable

Recent News About These Companies

Virpax Pharmaceuticals stock plummets on Nasdaq delisting news
April 3, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/virpax-pharmaceuticals-stock-plummets-on-nasdaq-delisting-news-93CH-3966072
Virpax Pharmaceuticals Inc trading halted, news pending
March 21, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-inc-trading-halted-news-pending-1034500708
Virpax reports positive results in Probudur dog study
March 20, 2025  |  investing.comhttps://www.investing.com/news/company-news/virpax-reports-positive-results-in-probudur-dog-study-93CH-3935131
Virpax receives positive Probudur results for dose range study
March 20, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-receives-positive-probudur-results-for-dose-range-study-1034490634
Virpax Pharmaceuticals announces 1-for-25 reverse stock split
March 20, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-announces-1-for-25-reverse-stock-split-1034494202
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND
March 18, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-receives-positive-probudur-results-200100643.html
Virpax Pharmaceuticals files to sell common stock and warrants, no amount given
March 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-files-to-sell-common-stock-and-warrants-no-amount-given-1034485903
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET
March 11, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/virpax-pharmaceuticals-explores-intranasal-mrna-vaccine-delivery-using-met/ar-AA1AGDwC
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference
March 11, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/virpax-pharmaceuticals-to-present-nes100-toxicity-study-at-major-toxicology-conference/ar-AA1AF8g0
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
March 7, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250307334228/en/virpax-looking-to-use-met-to-develop-intranasal-covid-vaccine/
Analysts Conflicted on These Healthcare Names: Clearside Biomedical (CLSD) and Virpax Pharmaceuticals (VRPX)
March 6, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/analysts-conflicted-on-these-healthcare-names-clearside-biomedical-clsd-and-virpax-pharmaceuticals-vrpx-1034450215
Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS
March 5, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-nes100-presented-society-toxicology-210100662.html
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology
March 3, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/virpax-pharmaceuticals-applauds-successful-trial-of-molecular-envelope-technology/ar-AA1A7VRw
Virpax lauds Nanomerics’ MET study with no severe side effects
March 1, 2025  |  investing.comhttps://www.investing.com/news/company-news/virpax-lauds-nanomerics-met-study-with-no-severe-side-effects-93CH-3897728
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
February 27, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/virpax-reports-positive-results-human-210100424.html
Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
February 27, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250227128970/en/virpax-reports-positive-results-in-human-study-for-its-molecular-envelope-technology/
Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
February 13, 2025  |  joplinglobe.comJ
Virpax Pharmaceuticals confirms results with U.S. Army with Probudur
February 13, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/virpax-pharmaceuticals-confirms-results-with-u-s-army-with-probudur-1034358717
Virpax reports positive study results for pain management drug
February 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/virpax-reports-positive-study-results-for-pain-management-drug/ar-AA1z0EUb
Virpax Pharmaceuticals appoints new independent director
February 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/virpax-pharmaceuticals-appoints-new-independent-director/ar-AA1yywrg

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biofrontera stock logo

Biofrontera NASDAQ:BFRIW

$0.02 0.00 (0.00%)
As of 09/18/2026

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Cingulate NASDAQ:CINGW

$0.0060 0.00 (-21.05%)
As of 09/18/2026 12:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

60 Degrees Pharmaceuticals stock logo

60 Degrees Pharmaceuticals NASDAQ:SXTPW

$0.03 0.00 (-1.42%)
As of 09/18/2026 03:00 PM Eastern

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Virpax Pharmaceuticals stock logo

Virpax Pharmaceuticals NASDAQ:VRPX

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas